Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Breast Cancer Early Stage Breast Cancer ...
Phase Not Applicable
Enrollment 800
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Multicentric retroprospective observational study to collect outcome in premenopausal breast cancer patients who undergone the 21-multigene assay Oncotype DX from 1st January 2013 to 31st December 2022 and adjuvant treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Primary Outcomes

  • Invasive Disease-Free Survival (iDFS) at 5 years (up to 30 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-24
Completion: 2027-09
Eligibility
Age: Up to 60 Years
Sex: FEMALE
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborators: Clinical Research Technology S.r.l.
Principal Investigators:
  • Antonella Palazzo (PRINCIPAL_INVESTIGATOR) - Fondazione Policlinico Gemelli, IRCCS
  • Alessandra Fabi (STUDY_CHAIR) - Fondazione Policlinico Gemelli, IRCCS
Contact Information
Study Contact:
Clinical Research Technology
0039 089 301545
perseverex@cr-technology.com
Antonella Palazzo MD
0039 0630155202
antonella.palazzo@policlinicogemelli.it
Fondazione Policlinico Gemelli
Antonella Palazzo
Fondazione Policlinico Gemelli
Interventions
N/A
Study Locations (2 sites)
Fondazione Policlinico Gemelli, Roma, Antonella Palazzo Italy
Clinical Research Technology, Salerno, Italy
Eligibility Criteria
Inclusion Criteria: 1. Female, premenopausal and ≥18 years age patients. 2. Agree to participate in study and signing informed consent or declaration in lieu of informed consent form, if applicable 3. Histological diagnosis of early breast cancer hormone positive (ER and/or PgR), HER2-negative. 4. Pathological nodal stage of pN0 or pN1 (1-3 nodes) and pathological tumor stage of pT1 to pT3. 5. Surgery for primary breast cancer and axillary staging by sentinel node biopsy or axillary lymph node dissection (ALND). 6. Availability of 21-multigene assay Oncotype DX recurrence score results performed according to physician choice from 1st January 2013 to 31st December 2022 7. Availability of clinical and pathological information. 8. Availability of information about adjuvant treatment received. 9. Availability of patient' outcome information (relapse, site of relapse, survival). Exclusion Criteria: 1. Evidence of distant metastases 2. Inflammatory breast cancer 3. Neoadjuvant treatment 4. No surgery for primary breast cancer and axillary staging 5. Patients not tested with 21-multigene assay Oncotype DX
Conditions Breast Cancer
Phase Not Applicable
Enrollment 105
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Extracellular vesicles (EVs) are lipid bilayer-delimited particles, naturally released from cells and mediators of intercellular cross-talk. In breast cancer (BC), EVs seem to be involved in the tumor microenvironment's shaping, in cancer cells invasion and in the set-up of metastasis. Clinical studies have provided initial evidence that these vesicles may have a prognostic and predictive value in breast cancer. Considering their ubiquitous presence in body fluids and their minimally invasive assessment through blood sampling, EVs could have a potential as liquid biopsy-derived biomarkers. Their quantification though is a complex task requiring complicated and time-consuming pre-analytical procedures of EVs isolation. This protocol want to develop a new method for the detection of tumor-derived-EVs associated proteins, based on the use of Single Molecule Array (SiMoA), a digital ELISA technology able to detect and quantify extremely low concentrations of target proteins or particles. The aim of this study is to evaluate how this new technology can allow the quantification of EVs plasma levels in patients affected by BC, providing useful diagnostic and prognostic information.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Blood sample — Analysis of plasma in order to quantify and characterize EVs

Primary Outcomes

  • EVs levels in early BC (36 months)
  • EVs levels in metastatic BC (36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-12-01
Completion: 2026-09-30
Eligibility
Age: 18 Years – 90 Years
Sex: FEMALE
Volunteers: true
Enrollment: 105 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istituti Clinici Scientifici Maugeri SpA
Contact Information
Study Contact:
Fabio Corsi, Professor
0382592272
fabio.corsi@icsmaugeri.it
SARA PAOLA ALBASINI, MsC
3497378405
sara.albasini@icsmaugeri.it
Fabio Corsi, Professor
0382592272
fabio.corsi@icsmaugeri.it
Istituti Clinici Scientifici Maugeri SpA
Interventions
  • Diagnostic Test: Blood sample — Analysis of plasma in order to quantify and characterize EVs
Study Locations (1 sites)
Istituti Clinici Scientifici Maugeri SpA, Pavia, Lombardy 27100 Italy
Eligibility Criteria
Inclusion Criteria: * Signing of a specific informed consent for participation to the study * Female sex Population 1: * Diagnosis of early breast cancer; * Indication for surgery after multidisciplinary discussion. Population 2: \- Patients having a negative mammography or breast ultrasound within 12 months from the study enrollment. Population 3: * Diagnosis of metastatic breast cancer confirmed by cytological/histological examination or by imaging; * Indication to chemotherapy. Exclusion Criteria: Population 1: * Presence of distant metastases * Synchronous presence of a different tumor * Indication to neoadjuvant chemotherapy Population 2: * Diagnosis of breast cancer * Synchronous presence of a different tumor or chronic disease Population 3: \- Patients who are unfit for systemic chemotherapy treatment

The TASTY-steering Study

NCT07258563
Recruiting
Conditions Metastatic Triple Negative Breast Cancer...
Phase NA
Enrollment 201
Locations 11 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicentre non-blinded randomised intervention trial with a parallel cluster design. The multicentre study will be performed at 12 hospitals in the Netherlands. A parallel cluster design per hospital was selected to prevent contact between participants in the same hospital who are randomised into different study arms. Such contact may result in bias as it may allow for patients in the control arm to be informed about elements of taste steering. To examine the effect of at-home taste steering versus standard care on food enjoyment, the obtained results and outcomes will be measured 1) at baseline before chemotherapy is started, 2) at week 0 when taste or smell alterations occur, and 3) after 6 weeks. The taste steering will take place at home. The control group will receive usual care. Questionnaires will be filled in online at home, while taste and smell tests and saliva collection will be conducted either at home or in the hospital during regular visits. Patients in both study arms are contacted by their dietitian every 3 weeks. Some hospitals have implemented elements of taste steering. However, these elements are focused on patients who are admitted to the hospital, and therefore only interfere to a limited extent with the present study that is directed at patients managing their taste alterations at home. Experience with the Smaakpupil tool indicates that the algorithm reaches saturation after 3-4 weeks. Therefore, an intervention period of 6 weeks has been selected.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Behavioral: Taste steering — To examine the effect of at-home taste steering versus standard care on food enjoyment, the obtained results and outcomes will be measured 1) at baseline before chemotherapy is started, 2) at week 0 when taste or smell alterations occur, and 3) after 6 weeks. The taste steering will take place at home. The control group will receive usual care. Questionnaires will be filled in online at home, while taste and smell tests and saliva collection will be conducted either at home or in the hospital during regular visits. Patients in both study arms are contacted by their dietitian every 3 weeks.

Primary Outcomes

  • Food enjoyment in appetite, hunger and sensory perception (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-06
Completion: 2028-07
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 201 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Medical Center Groningen
Principal Investigators:
  • J. J. de Haan, MD, PhD (PRINCIPAL_INVESTIGATOR) - University Medical Center Groningen, Dept. of Medical Oncology
Contact Information
Study Contact:
J. J. de Haan, MD, PhD
+31 50 361 2821
j.j.de.haan@umcg.nl
M. D. Douma
+31 50 361 4603
m.d.douma@umcg.nl
K. Silverio Alonso-Duin
Amsterdam UMC
Interventions
  • Behavioral: Taste steering — To examine the effect of at-home taste steering versus standard care on food enjoyment, the obtained results and outcomes will be measured 1) at baseline before chemotherapy is started, 2) at week 0 when taste or smell alterations occur, and 3) after 6 weeks. The taste steering will take place at home. The control group will receive usual care. Questionnaires will be filled in online at home, while taste and smell tests and saliva collection will be conducted either at home or in the hospital during regular visits. Patients in both study arms are contacted by their dietitian every 3 weeks.
Study Locations (11 sites)
Amsterdam UMC, Amsterdam, Netherlands
Rijnstate Ziekenhuis, Arnhem, Netherlands
Van Weel-Bethesda Ziekenhuis, Dirksland, Netherlands
Ziekenhuisvoorzieningen Gelderse Vallei, Ede, Netherlands
University Medical Center Groningen, Groningen, 9713 GZ Netherlands
Martini Ziekenhuis, Groningen, Netherlands
Radboud University Medical Center, Nijmegen, Netherlands
Ikazia Ziekenhuis, Rotterdam, Netherlands
Ommelander Ziekenhuis Groningen, Scheemda, Netherlands
Maxima Medisch Centrum, Veldhoven, Netherlands
Eligibility Criteria
Inclusion Criteria: * Age ≥18 and ≤70 years * Indication to start chemotherapy for: * Metastatic triple negative breast cancer * Metastatic testicular cancer * Stage II-IV diffuse large B cell lymphoma * Chemotherapy scheduled to start in the next 6 weeks * Consuming solid foods and drinks is possible * ≤50% of recommended daily intake in kcal consists of oral nutritional supplements * Oral mucositis grade ≤2 (Common Terminology Criteria for Adverse Events, version 5.0) * Ability to comply with all protocol-required actions * Written informed consent * For the intervention phase only: subjective change in taste since start of chemotherapy Exclusion Criteria: * Pregnancy * Currently experiencing taste or smell problems * Previous or current radiotherapy of head and neck region * Enteral feeding through tube or parenteral feeding * Participation in another clinical trial aimed at preventing or treating taste and/or smell alterations * Chronic (\>1 month) high dose corticosteroids (\>10 mg prednisone/day or equivalent).
Conditions Advanced Solid Tumor, TNBC - Triple-Nega...
Phase PHASE1
Enrollment 260
Locations 17 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the safety and tolerability of increasing doses of BAL0891 in patients with advanced solid tumors or relapsed or refractory acute myeloid leukemia. An adaptive model-based design will be used to guide the dose escalation. Subject assignment to Substudy 1, 2, 3 and 4 will be finalized following approval from the investigator and sponsor. The dose-expansion stage will be conducted with the RP2D to further evaluate the preliminary anti-tumor activity, safety, and tolerability in metastatic TNBC and GC.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BAL0891 — BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)
  • Combination Product: Tislelizumab — Tislelizumab a humanized IgG4 anti-PD-1 monoclonal antibody
  • Combination Product: Paclitaxel — Paclitaxel is a natural product with antitumor activity

Primary Outcomes

  • Part 1: Number of Participants With Adverse Events as a Measure of Safety and Tolerability (After first dose, up to 2 years)
  • Part 1: Number of Participants With the DLT (Dose-limiting toxicity)s as a Measure of maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) (After first dose and within 7 days of End of Treatment, up to 2 years)
  • Part 2: Overall response rate (ORR) for all subjects (Every 3 months (±14 days) after first dose, up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2022-12-14
Completion: 2026-12-24
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 260 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: SillaJen, Inc.
Principal Investigators:
  • SillaJen Inc. (STUDY_DIRECTOR) - SillaJen, Inc.
Contact Information
Study Contact:
SillaJen Inc.
02-368-2600
patient_inquiry@sillajen.com
Yale New Haven Hospital
Yale New Haven Hospital
University of Miami Health System
University of Miami Health System
Interventions
  • Drug: BAL0891 — BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)
  • Combination Product: Tislelizumab — Tislelizumab a humanized IgG4 anti-PD-1 monoclonal antibody
  • Combination Product: Paclitaxel — Paclitaxel is a natural product with antitumor activity
Study Locations (17 sites)
Yale New Haven Hospital, New Haven, Connecticut 06510 United States
University of Miami Health System, Coral Gables, Florida 33146 United States
Winship Cancer Institute / Emory University, Atlanta, Georgia 30322 United States
University of Michigan, Ann Arbor, Michigan 48109 United States
New York Medicine-New York-Presbyterian Hospital, New York, New York 10021 United States
Montefiore Medical Center - Montefiore Hospital, New York, New York 10467 United States
Montefiore Medical Center, The Bronx, New York 10461 United States
OHSU Knight Cancer Institute, Portland, Oregon 97239 United States
Mary Crowley Cancer Research, Dallas, Texas 75230 United States
Baylor University Medical Center, Dallas, Texas 75246 United States
Eligibility Criteria
1.1. Inclusion criteria: Substudy 1, 2, 3 and Dose expansion Each patient must meet all the following inclusion criteria. 1. Informed consent signed by the patient prior to any study-related procedure indicating that they understand the purpose of, and procedures required for, the study, and are willing to participate in the study. 2. Male or female aged ≥18 years (or ≥ 19 years according to local regulatory guidelines) at the time of screening. 3. Patients with incurable advanced/metastatic solid tumor disease refractory to or intolerant of existing therapy known to provide clinical benefit for their condition. Note: Patients with non-CNS tumors participating during dose escalation may have inactive CNS metastasis, defined as 4 weeks after either brain metastasis resection or radiation, and a) all residual neurological symptoms resolved to grade ≤ 2; b) on stable doses of dexamethasone, if applicable; and c) follow-up imaging shows no new lesions appearing. 4. Patients enrolled in Dose Expansion only • TNBC cohorts i. Must have histologically confirmed breast adenocarcinoma that is unresectable, loco-regional, or metastatic. ii. Must have source data documented pathologically confirmed triple negative breast cancer, defined as both of the following. 1. Estrogen receptor (ER) and progesterone receptor (PgR) negative: \<1% of tumor cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PgR (positive intrinsic controls) 2. Human epidermal growth factor receptor 2 (HER2) negative as per American Society of Clinical Oncology/College of American Pathologists guidelines * IHC 0 or 1 fluorescence in situ hybridization (FISH) negative (or equivalent negative test) * Patients with IHC 2 must have a negative by FISH (or equivalent negative test) iii. Patients with a history of different breast cancer phenotypes (i.e., ER/PgR/HER2 Positive) must obtain pathological confirmation of triple-negative disease in at least one of the current sites of metastasis. iv. Must have progression on or after therapy containing anthracycline and/or a taxane. Subjects must have received anthracycline and/or a taxane based regimen or other chemotherapy / targeted therapy regimen if anthracycline or taxane was contraindicated or another available approved targeted agent was contraindicated. At time of enrolment, patients must have progressed on, be intolerant of, or be ineligible for, all available standard of care therapies with proven benefit. • GC cohort i. Must have a histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma. ii. Must have progression on or after therapy containing platinum/fluoropyrimidine. Subjects must have received platinum-based chemotherapy or other chemotherapy regimen if platinum-based chemotherapy was contraindicated or another available approved targeted agent unless the targeted agent was contraindicated. At time of enrolment, patients must have progressed on, be intolerant of, or be ineligible for, all available standard of care therapies with proven benefit. iii. Documentation of HER2/neu status. Patients who are HER2/neu-positive must be treated with a HER2/neu inhibitor, and subjects should have progressed on or be intolerant to the targeted therapy or subjects must have received other chemotherapy regimen if HER2/neu inhibitor was contraindicated or another available approved targeted agent unless the targeted agent was contraindicated. At time of enrolment, patients must have progressed on, be intolerant of, or be ineligible for, all available standard of care therapies with proven benefit. iv. Subjects must/should have received no more than 3 lines of prior therapy for the advanced disease (if a subject progressed within 6 months of completing adjuvant therapy, this would count as a prior line of therapy). 5. For patients enrolled in Substudy 3 or cohort 3 and 4, if a taxane (i.e., paclitaxel or docetaxel) was administered as part of the previous regimen, PD must have occurred \> 12 months from the end of the previous treatment. (Patients who received a taxane in previous treatments without reaching PD may enroll without the 12-month waiting period.) 6. Patients enrolled in Dose Expansion only, patient must have undergone a minimum of 1 prior systemic regimen for advanced or metastatic disease. (Korea only, patients must have received the second line standard of care treatment as per the regulations of the respective country. Patients who are unsuitable to receive the standard of care second line treatment will be eligible for enrollment) 7. Eastern Cooperative Oncology Group performance status (ECOG PS) 0or-1 8. For patients enrolled from DL1.4 of Substudy 1 onwards and for all patients in Substudies 2 and 3 and all four dose expansion cohorts, measurable tumor disease per Response Evaluation Criteria in Solid Tumors 1.1 criteria (RECIST 1.1), i.e., a minimum of one target lesion. 9. Adequate organ functions as indicated by the following Screening visit local laboratory values: 1. Hemoglobin ≥ 9 g/dL (criterion must be met without erythropoietin dependency and without packed red blood cell transfusion within the last 4 weeks) 2. ANC ≥ 2.0 × 109/L; criterion must be met without growth factor (e.g., G-CSF, GM CSF, etc.) administration within the last 2 weeks 3. Platelets ≥ 100 × 109/L 4. Total bilirubin ≤ 1.5 × ULN 5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) baseline levels ≤ 1.5 × ULN, with the option for AST/ALT ≤ 3.0 × ULN, or ≤ 5.0 × ULN for patients with liver metastasis, upon accumulating evidence for the absence of liver toxicity in biologically active DLs 6. Albumin ≥ 2.8 g/dL 7. CLCR ≥ 50 mL/min (as calculated by the Cockcroft-Gault formula), or eGFR ≥ 50 mL/min/1.73 m² (MDRD equation or CKD-EPI equation) 8. For women of childbearing potential, negative serum human chorionic gonadotropin (hCG) 10. Men/women of child-producing/bearing potential must agree to: avoid impregnating a partner or becoming pregnant, respectively, during the study, and for at least 6 months after the last dose of either investigational drug, and comply with the contraception requirements. 1.2. Inclusion criteria: Substudy 4 Each patient must meet all the following inclusion criteria. 1. Informed consent signed by the patient prior to any study-related procedure indicating that they understand the purpose of, and procedures required for, the study, and are willing to participate in the study. 2. Male or female aged ≥18 years (or ≥ 19 years according to local regulatory guidelines) at the time of screening. 3. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2. 4. Estimated life expectancy of at least 8 weeks 5. AML either de novo or secondary as any subtype diagnosed according to the WHO 2022 classification system \[except acute promyelocytic leukemia (APL)\] who either: Relapse/refractory (R/R) acute myeloid leukemia (AML) defined as those who have also failed or are not appropriate for any approved standard-of-care (SOC) therapies, or hematopoietic stem cell transplant (HSCT) with reappearance of ≥ 5% blasts in the bone marrow. 6. Relapsed AML is defined as having 5% or more leukemic blasts in the bone marrow, reappearance of leukemic blasts in peripheral blood (in at least two peripheral blood samples taken at least one week apart), or the development of new extramedullary disease. 7. WBC, peripheral blood leukocyte count≤ 25,000/µL and blast count ≤ 25,000/µL prior to initiation of therapy 1. Hydroxyurea is allowed during screening and prior to day 1 of study treatment to keep the blast count ≤25,000/µL; hydroxyurea is to be ceased 24 hours prior to study therapy. 2. Hydroxyurea may be used for up to 28 days in the initial treatment cycle if needed, to keep the white blood cell (WBC) count ≤25,000/µL. However, no other anti-leukemic treat
Conditions Recurrent or Metastatic Solid Tumors
Phase PHASE1, PHASE2
Enrollment 680
Locations 120 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; cutaneous melanoma; and neuroendocrine carcinoma (NEC).

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Ifinatamab deruxtecan — Intravenous administration

Primary Outcomes

  • Objective Response Rate (ORR) as Assessed by Investigator (From the time of the first dose of study drug until the date of documented disease progression, death, loss to follow-up, or withdrawal by the subject, whichever occurs first (up to approximately 60 months))
  • Number of Participants Reporting Dose-limiting Toxicities (DLTs) in the HCC Cohort (Cycle 1 Day 1 to Cycle 1 Day 21)
  • Number of Participants Reporting TEAEs and Death in the HCC Cohort (From date of signing the informed consent form up to 47 days after the last dose of study drug, up to approximately 60 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2024-04-10
Completion: 2028-07-25
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 680 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Daiichi Sankyo
Collaborators: Merck Sharp & Dohme LLC
Contact Information
Study Contact:
(US) Daiichi Sankyo Contact for Clinical Trial Information
9089926400
CTRinfo@dsi.com
(Asia) Daiichi Sankyo Contact for Clinical Trial Information
+81-3-6225-1111 (M-F 9-5 JST
dsclinicaltrial@daiichisankyo.co.jp
Principal Investigator
Los Angeles Cancer Network
Interventions
  • Drug: Ifinatamab deruxtecan — Intravenous administration
Study Locations (120 sites)
Valkyrie Clinical Trials, Los Angeles, California 90067 United States
Los Angeles Cancer Network, Los Angeles, California 91204 United States
Pih Health Hematology Medical Oncology, Whittier, California 90602 United States
Orchard Healthcare Research Inc, Skokie, Illinois 60077 United States
M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota 55114 United States
NYU Langone Health, New York, New York 10016 United States
Icahn School of Medicine At Mount Sinai Prime, New York, New York 10029 United States
Clinical Research Alliance, Inc, Westbury, New York 11590 United States
White Plains Hospital, White Plains, New York 10601 United States
Erlanger Health, Inc, Chattanooga, Tennessee 37403 United States
Eligibility Criteria
Participants must meet all of the following criteria to be included in the study: Common Inclusion Criteria for All Participants 1. Participants must consent to provide a pretreatment tumor sample which has not been previously irradiated. Fresh biopsies are strongly preferred, however, if a fresh pretreatment biopsy is not feasible or the procedure is unsuccessful, an appropriate archival sample must be provided. The most recent archival sample obtained up to 5 years prior to consent is acceptable. 2. Participants ages ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is \>18 years). 3. At least 1 measurable lesion on computed tomography (CT) or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), as assessed by the investigator. 4. Documentation of radiological disease progression on or after the previous standard-of-care regimen. For NEC participants for which the standard therapy does not exist OR for which the standard therapy is not appropriate by the investigator: presence of advanced/metastatic disease without previous regimen is acceptable. 5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Additional Inclusion Criteria for EC Participants 1. Pathologically or cytologically documented EC of any histological carcinoma subtype or endometrial carcinosarcoma, irrespective of microsatellite instability or mismatch repair status. 2. Relapse or progression after a platinum-containing systemic treatment and an immune checkpoint inhibitor (ICI)-containing regimen (combined or sequential). Participants with actionable target tumor mutation should have been previously treated with targeted therapy, with a maximum of 3 prior lines of therapy for endometrial carcinoma or carcinosarcoma. Neoadjuvant/adjuvant therapy may count as 1 line of therapy if the subject progressed within 6 months after completion of therapy. Additional Inclusion Criteria for HNSCC Participants 1. Pathologically or cytologically documented unresectable or metastatic squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx, excluding nasopharynx, nasal cavity and paranasal sinuses, and unknown primary. 2. Has disease progression after platinum-based and ICI treatment, whether administered in combination or separately. Participants with actionable target tumor mutation should have been previously treated with targeted therapy, with a maximum of 2 prior therapy lines for unresectable or metastatic HNSCC. 3. Participants without radiographic evidence of major blood vessel invasion/infiltration or tumor demonstrating a greater than (\>)90-degree abutment or encasement of a major blood vessel. 4. Participants with no prior history of Grade greater than or equal to (≥)3 bleeding as per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 within 28 days prior to the start of study drug related to the current head and neck cancer may be included in the study. 5. Documented p16 status for oropharyngeal cancer (historical results are acceptable if available). Additional Inclusion Criterion for PDAC Participants 1\. Pathologically or cytologically documented unresectable or metastatic pancreatic adenocarcinoma that has relapsed or progressed after 1 prior line of gemcitabine-based systemic therapy in the locally advanced/metastatic setting or after 2 lines of therapy if the participant has actionable target tumor mutation and has been previously treated with targeted therapy. a. No prior treatment with topoisomerase I inhibitors, such as irinotecan or topotecan. Additional Inclusion Criteria for CRC Participants 1. Pathologically or cytologically documented unresectable or metastatic CRC with microsatellite stable status (MSS). 2. Relapse or progression after 1 prior line of systemic therapy including a fluoropyrimidine plus oxaliplatin with or without anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb) or anti-epidermal growth factor receptor mAb therapy, as clinically indicated, or relapse or progression after 2 lines of therapy if the subject has received targeted therapy. Note: Prior adjuvant/neoadjuvant systemic cytotoxic chemotherapy will count as 1 line of prior systemic therapy if there is documented disease progression during therapy or within 6 months of chemotherapy completion. 3. No prior treatment with topoisomerase I inhibitors, such as irinotecan or topotecan. Additional Inclusion Criteria for HCC Participants 1. Pathologically or cytologically documented unresectable or metastatic HCC (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible) or noninvasive diagnosis of HCC as per the American Association for the Study of Liver Diseases (AASLD) criteria in participants with a confirmed diagnosis of cirrhosis. 2. Relapse or progression after 1 prior line of an ICI-containing regimen (combination or monotherapy) in the locally advanced/metastatic setting, or relapse or progression after 2 lines of therapy if the participant has an actionable target tumor mutation and has been treated with targeted therapy. 3. Barcelona Clinic Liver Cancer (BCLC) Stage B or C. 4. Liver function status should be Child-Pugh (CP) Class A. 5. Albumin-Bilirubin (ALBI) Grade 1 within 7 days prior to the first dose of study drug. 6. Participants with large esophageal varices at risk of bleeding must be treated with conventional medical intervention: beta blockers or endoscopic treatment. Additional Inclusion Criteria for Ad-eso/GEJ/Gastric Participants 1. Pathologically or cytologically documented unresectable or metastatic Ad-eso/GEJ/Gastric that has relapsed or progressed after 1 prior line of systemic therapy in the locally advanced/metastatic setting. a. Participants with PD-(L)1+ or MSI-H/dMMR should receive ICI treatment if ICIs are standard of care in the country, unless the participant is ineligible for ICI treatment. 2. If the participant has known history of HER2 positivity (defined by IHC 3+ or IHC 2+ and in situ hybridization \[ISH\] positive, as classified by American Society of Clinical Oncology - College of American Pathologists \[ASCO CAP\]) or actionable target, the participant must have been previously treated with a targeted therapy. Additional Inclusion Criteria for UC Participants 1. Pathologically or cytologically documented unresectable or metastatic UC of the bladder, renal pelvis, ureter, or urethra. Participants with histological variants are allowed if urothelial histology is predominant. Small cell/neuroendocrine tumors are not allowed even if mixed histology. 2. Relapse or progression after at least 1 prior line of ICI-containing systemic therapy, and 1 prior line of systemic chemotherapy, given in combination with other anticancer therapy or separately, with a maximum of 3 prior therapy lines. 1. At least 1 line of therapy should include enfortumab vedotin in countries where enfortumab vedotin is approved and available. 2. Perioperative systemic therapies will be counted as 1 line of therapy. 3. To meet inclusion criteria requirement of prior ICI-containing therapy, use in the perioperative or metastatic setting will suffice. 4. Participants with actionable target tumor mutation should have been previously treated with targeted therapy. 5. The same regimen administered twice in different disease settings will be counted as 1 line of prior therapy. Additional Inclusion Criteria for CC Participants 1. Histologically confirmed unresectable or metastatic CC that was previously treated with ≥1 prior line of systemic therapy in the locally advanced or metastatic setting. Participants with actionable target tumor mutation should have been previously treated with targeted therapy. 2. Participants should receive prior anti-programmed death 1 (PD-1)//programmed death-ligand 1 (PD-L1) treat
Conditions Breast Cancer, Breast Cancer Metastatic
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This study explores perspectives of women with non-metastatic breast cancer regarding their willingness and ability to make dietary changes pertaining to foods/food products that may pose a risk to their cancer prognosis and survival. This is a single-group study conducted entirely online. All study activities, including consent, educational brochure and surveys, will be completed remotely. Participants will receive email invitations to complete questionnaires in REDCap. Questionnaire 1 will collect sociodemographic information (no PHI) and a brief dietary recall. Questionnaire 2 will assess identification of ultra-processed foods. Before Questionnaire 3, participants will review a two-page educational flyer explaining the link between diet, obesity, and cancer, with information on unhealthy calories and food processing. Questionnaire 3 will assess participants' willingness and ability to eat healthier foods and reduce unhealthy foods. At study completion, participants will receive a thank-you message and a brief satisfaction survey.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Educational Brochure — The two-page educational brochure is emailed to participants after Questionnaire 2 and before they begin Questionnaire 3.

Primary Outcomes

  • Willingness and ability to make dietary changes (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-20
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNC Lineberger Comprehensive Cancer Center
Principal Investigators:
  • Kirsten Nyrop, PhD (PRINCIPAL_INVESTIGATOR) - UNC Lineberger Comprehensive Cancer Center
Contact Information
Study Contact:
Allison Ross
1 919-445-4905
allison_ross@med.unc.edu
Amy L Garrett, MA, CCRC
919-966-0695
amy_garrett@med.unc.edu
UNC Cancer Hospital
Kirsten A Nyrop, PhD
UNC Cancer Hospital
Interventions
  • Behavioral: Educational Brochure — The two-page educational brochure is emailed to participants after Questionnaire 2 and before they begin Questionnaire 3.
Study Locations (1 sites)
UNC Cancer Hospital, Chapel Hill, North Carolina 27519 United States
Eligibility Criteria
Inclusion Criteria: * Age \>18 -Female * Diagnosis of non-metastatic breast cancer * Completion of primary treatment for breast cancer * No recurrence or metastasis; or no other cancer other than basal or squamous cell * Willingness to provide a private email address for all study activities * Ability to read and understand English Exclusion Criteria: * Inability to comply with one or more of the inclusion criteria
Conditions Fatigue Related to Cancer Treatment, Bre...
Phase PHASE3
Enrollment 250
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate whether Nuvastatic 300 mg capsules can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy. The main questions it aims to answer are: * Does Nuvastatic 300 mg capsules significantly reduce cancer-related fatigue compared to placebo? * Is Nuvastatic 300 mg capsules safe and well tolerated in this patient population? Researchers will compare Nuvastatic 300 mg capsules vs placebo to see if Nuvastatic 300 capsule improves fatigue scores and maintains an acceptable safety profile. Participants will: * Receive Nuvastatic 300 mg capsules or placebo capsules (3 times per day) for 3 cycles of 20 days each (total \~60 treatment days). * Continue their standard first-line chemotherapy regimen. * Provide blood sample assessments at Screening and End of Treatment. * Complete patient diaries and fatigue assessments as per protocol.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Drug: Nuvastatic 300 — 300mg capsule, (3 capsules X 3 times a day)
  • Drug: Placebo — 300mg capsule, (3 capsules X 3 times a day)

Primary Outcomes

  • Reduction in cancer-related fatigue in breast cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo. (From Screening to EOT (about 6 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-10-01
Completion: 2026-10-30
Eligibility
Age: 18 Years – 65 Years
Sex: FEMALE
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Natureceuticals Sdn Bhd
Contact Information
Study Contact:
Aman Shah Abdul Majid, MBChB, DPhil
+605-2490500
amanharvard2020@outlook.com
Dr Bella Ravi Shankar
Omega Hospital Chinna Gadhili
Dr. Nikhil Mallinath Shirsi
Sangavi Multispeciality Hospital Pvt. Ltd,
Interventions
  • Drug: Nuvastatic 300 — 300mg capsule, (3 capsules X 3 times a day)
  • Drug: Placebo — 300mg capsule, (3 capsules X 3 times a day)
Study Locations (6 sites)
Omega Hospital Chinna Gadhili, Visakhapatnam, Andhra Pradesh 530040 India
K R Hospital, Mysore, Karnataka 570001 India
Jeevanjyoti Cancer Hospital, Jalgaon, Maharashtra 425001 India
Sangavi Multispeciality Hospital Pvt. Ltd,, Pune, Mahrasta 411027 India
Erode Cancer Care Centre, Erode, Tamil Nadu 638012 India
International Oncology Cancer Tower 1, Kanpur, Uttar Pradesh India
Eligibility Criteria
Inclusion Criteria: * Female patients aged ≥ 18 years and ≤ 65 years who are willing to voluntarily provide consent for participation in the study. * Patients with confirmed triple negative metastatic breast cancer who are planned or scheduled to receive standard chemotherapy treatment for at least 4 to 6 cycles respectively. * Patients must have a confirmed diagnosis of triple negative metastatic breast cancer as per standard guidelines. * Patients must have at least one tumour lesion with ≥ 1cm in one dimension that is radiographically apparent on computed tomography (CT) or magnetic resonance imaging (MRI). * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at screening. * The patient has stable haemoglobin (≥ 9 g/dL) throughout the screening. * Life expectancy ≥ 6 months, as per the investigator's judgment. * Patients with co-morbidities or medical conditions including Type 2 diabetes mellitus (DM) and hypertension who are deemed stable by the investigator can be included in the study. * At screening, patients with stable fatigue, newly developed fatigue, or worsening fatigue scores as assessed by the Brief Fatigue Inventory (BFI) should be included. Exclusion Criteria: * Patients who have any untreated reversible medical condition which may cause fatigue (e.g. major metabolic or electrolyte disturbance, active infection, endocrine abnormalities) as per the investigator's clinical judgment. * Patients with an inability to understand local language(s) for scales used for evaluations i.e. VAFS, BFI AND SF-36. * Patients who have received concurrent stimulant medication (e.g. dextroamphetamine or methylphenidate) during the screening period or any medication which may interfere with the study drug. * Patients with any delay in chemotherapy treatment such that the screening period extends beyond 21 days. * Patients with known central nervous system (CNS) involvement. * Patients with any serious, uncontrolled, non-malignant medical or psychiatric disorder, or any other medical condition which in the opinion of the investigator, may affect the patient's safety or study participation and conduct. * Female patients who are pregnant or breastfeeding. * Patients with known hepatitis C virus, hepatitis B virus, HIV infection. * Patients who have nausea and vomiting or any gastrointestinal disorder that is severe enough to interfere with study drug absorption in the opinion of the investigator. * Patients with uncontrolled pain, who in the opinion of the investigator are not eligible for the study. * Patients with known hypersensitivity or intolerance of rosmarinic acid, caffeic acid, and other related phenolic compounds as well as excipients in the Nuvastatic® 300 mg or placebo treatment. * Patients with planned therapy or treatment with another investigational agent. * Previous exposure to any investigational agent within 4 weeks prior to screening, or planned administration of an investigational agent, other than as specified by this protocol, during the study period.

NearWave Optical Molecular Monitoring

NCT06744465
Recruiting
Conditions Breast Cancer, HER2-positive Breast Canc...
Phase NA
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitoring therapy progression and predicting pathologic complete response (pCR) of breast cancer patients undergoing neoadjuvant chemotherapy (NAC).

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: NearWave monitoring — NearWave optical molecular monitoring

Primary Outcomes

  • Feasibility of using NearWave imaging as a monitoring system (Over approximately 5 months; baseline, mid way through treatment, and at last dose of clinical chemotherapy/prior to clinical surgery)
  • Feasibility of using NearWave imaging as a monitoring system (Over approximately 5 months; baseline, mid way through treatment, and at last dose of clinical chemotherapy/prior to clinical surgery)
  • Feasibility of using NearWave imaging as a monitoring system (Over approximately 5 months; baseline, mid way through treatment, and at last dose of clinical chemotherapy/prior to clinical surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-07
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Indiana University
Collaborators: University of Notre Dame, Elevate Ventures, NearWave Corp.
Contact Information
Study Contact:
Tarah J Ballinger, MD
(317) 944-3553
tarahb@iu.edu
Xin Bryan, RN
317-312-2793
zhongx@iu.edu
Tarah J Ballinger, MD
3172742556
tarahb@iu.edu
Indiana University Simon Comprehensive Cancer Center
Interventions
  • Device: NearWave monitoring — NearWave optical molecular monitoring
Study Locations (1 sites)
Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana 46202 United States
Eligibility Criteria
Inclusion Criteria: 1. Women ≥ 18 years old at the time of informed consent 2. Ability to provide written informed consent and HIPAA authorization 3. Patients who: 1. have been diagnosed with invasive breast cancer by tissue biopsy and have not yet started any therapy for the disease; a) Subtype HER2 positive (IHC 3+ or if IHC 2+, then positive by FISH), with any ER status, OR b) Subtype TNBC, defined by: HER2 negative and ER/PR negative or low (ER and PR ≤ 9%, weak staining) 2. with ≥2 cm tumor size in the largest dimension as measured by ultrasound, MRI, or mammography. If multifocal disease, at least one tumor must measure ≥2 cm 3. are planned to receive neoadjuvant chemotherapy followed by surgery 4. Will be at least two weeks out from biopsy of the primary lesion at the time of baseline visit 5. Have a palpable breast mass as determined by a treating physician Exclusion Criteria: 1. Patients with significant bruising or hematoma from diagnostic breast biopsy, as determined by clinical judgement (mild ecchymosis okay) 2. Inflammatory breast cancer 3. Prior breast cancer requiring surgery or radiation in either breast 4. Pregnant or nursing due to changes in breast architecture 5. Patients with a BMI of ≥ 40, unless the lesion is near the surface (\<3 cm from the skin surface), based on diagnostic scan measurements 6. Patients with any tattoos on their breasts
Conditions Breast Cancer, Endocrine Therapy, CDK4/6...
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Exploring the Efficacy and Safety of Different Systemic Treatment Regimens after CDK4/6i Progression in the Real World has significant implications. This study is an observational, real-world study. It plans to include over 300 eligible HR+/HER2- metastatic breast cancer patients who are currently receiving or planning to receive endocrine therapy regimens containing CDK4/6 inhibitors. This study is a single-arm, non-interventional study that evaluates the efficacy and safety of the first-line treatment regimen, which includes CDK4/6 inhibitors combined with endocrine therapy, based on clinical guideline consensus. After disease progression on first-line treatment, the second-line systemic treatment regimen (including but not limited to switching to another CDK4/6 inhibitor combined with endocrine therapy, other types of endocrine therapy, chemotherapy, targeted therapy, etc.) will be chosen by the physician, and the efficacy and safety of subsequent treatment will be evaluated. Additionally, peripheral blood ctDNA testing will be used to assess changes in baseline and progression-related biomarkers, including ESR1, PI3KCA, FGFR1, PTEN, among some patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Different treatment regimens following progression on CDK4/6 inhibitors. — This study is a single-arm, non-interventional study that evaluates the efficacy and safety of the first-line treatment regimen, which includes CDK4/6 inhibitors combined with endocrine therapy. After disease progression on first-line treatment, the second-line systemic treatment regimen (including but not limited to switching to another CDK4/6 inhibitor combined with endocrine therapy, other types of endocrine therapy, chemotherapy, targeted therapy, etc.) will be evaluated.

Primary Outcomes

  • Progression-Free Survival (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-01-01
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hunan Cancer Hospital
Contact Information
Study Contact:
Ning Xie, Dr.
+860731-89762161
xiening@hnca.org.cn
Ting Liu, Ms.
+860731-89762815
liuting@hnca.org.cn
Binliang Liu, M.D
073189762161
liubinliang_onco@163.com
Hunan Cancer Hospital
Interventions
  • Drug: Different treatment regimens following progression on CDK4/6 inhibitors. — This study is a single-arm, non-interventional study that evaluates the efficacy and safety of the first-line treatment regimen, which includes CDK4/6 inhibitors combined with endocrine therapy. After disease progression on first-line treatment, the second-line systemic treatment regimen (including but not limited to switching to another CDK4/6 inhibitor combined with endocrine therapy, other types of endocrine therapy, chemotherapy, targeted therapy, etc.) will be evaluated.
Study Locations (1 sites)
Hunan Cancer Hospital, Changsha, Hunan 410013 China
Eligibility Criteria
Inclusion Criteria: * Inclusion criteria: * Age ≥ 18 years, postmenopausal or pre/perimenopausal females, or male patients. Female patients must meet one of the following criteria: 1. Prior bilateral oophorectomy or age ≥ 60 years. 2. Age \< 60 with natural postmenopausal status (defined as spontaneous cessation of regular menstruation for at least 12 consecutive months without any other pathological or physiological reasons), and estradiol (E2) and follicle-stimulating hormone (FSH) levels consistent with postmenopausal range. 3. Pre/perimenopausal females may also be eligible but must be willing to receive LHRH agonist during the study. * Pathologically confirmed HR-positive male/female breast cancer patients with evidence of localized recurrence or metastasis, who are not suitable for curative surgery or radiation therapy: ER-positive and/or PR-positive defined as the proportion of positively stained tumor cells ≥ 1% of all tumor cells (as confirmed by the investigators at the participating center). * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * No prior systemic treatment or currently receiving CDK4/6 inhibitors as first-line treatment for advanced disease. * Reproductive-age females must have a negative serum pregnancy test within 28 days before enrollment and male/female patients must be willing to use a medically approved highly effective contraceptive measure during the study period and up to 1 year after the last dose of investigational drug. * Non-pregnant or non-lactating females. * Not concurrently participating in any other ongoing study. * Patient or legally authorized representative has provided informed consent and is willing and able to comply with the planned visits, study treatment plan, laboratory tests, and other trial procedures. Exclusion Criteria: * 1\. Any evidence of severe or uncontrolled systemic illnesses, including uncontrolled hypertension, active bleeding disorders, active infections including hepatitis B, hepatitis C, and human immunodeficiency virus, or severely impaired bone marrow reserve or organ function, including liver and kidney impairment, which, in the investigator's opinion, would greatly alter the risk/benefit balance. * Patient has not yet recovered from any CTCAE grade ≥ 3 toxicity related to prior treatment at the start of CDK4/6 inhibitor therapy. * Known history of allergy to CDK4/6 inhibitors, excipients, or drugs with a similar chemical structure or class as CDK4/6 inhibitors. * Patients deemed unsuitable for enrollment by the investigator.
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase PHASE3
Enrollment 80
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This phase III trial evaluates how often women develop insulin resistance and type-2 diabetes and compares metformin with usual care to usual care alone in treating insulin resistance in women with stage I-III breast cancer after chemotherapy. Insulin resistance occurs when cells stop responding to insulin and is a risk factor for developing diabetes and heart disease. Higher levels of insulin have been shown to be associated with aggressive breast cancer. Metformin hydrochloride decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body's use of the glucose. Metformin as well as standard of care diet and exercise education is known to lower blood sugar. However, chemotherapy may accelerate metabolic disorders, such as high blood sugar, and the impact of metformin in these breast cancer survivors is not known. Giving metformin with usual care may be more effective than usual care alone in preventing or reversing insulin resistance in women with stage I-III breast cancer after chemotherapy.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Other: Educational Intervention — Receive standard of care healthy diet and exercise handouts
  • Drug: Extended Release Metformin Hydrochloride — Given PO
  • Other: Questionnaire Administration — Ancillary studies

Primary Outcomes

  • Hemoglobin A1c (Hgb A1c) normalization (Up to 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-01-13
Completion: 2031-06-16
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Victoria L Seewaldt (PRINCIPAL_INVESTIGATOR) - City of Hope Medical Center
Contact Information
Study Contact:
Victoria L. Seewaldt
626-218-6321
vseewaldt@coh.org
City of Hope Medical Center
Victoria L. Seewaldt
City of Hope Medical Center
Shankar Subramaniam
858-822-0986
shsubramaniam@ucsd.edu
UC San Diego Moores Cancer Center
Interventions
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Other: Educational Intervention — Receive standard of care healthy diet and exercise handouts
  • Drug: Extended Release Metformin Hydrochloride — Given PO
  • Other: Questionnaire Administration — Ancillary studies
Study Locations (3 sites)
City of Hope Medical Center, Duarte, California 91010 United States
UC San Diego Moores Cancer Center, La Jolla, California 92093 United States
University of California-Riverside, Riverside, California 92521 United States
Eligibility Criteria
Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Agreement to allow lab draw of approximately 26 mL of blood (less than 2 tablespoons) * To check blood counts, organ function and disease at baseline and 12 months * Review of clinical charts at pre-registration\* (refer to Study Calendar), baseline, 3 months, 6 months,12 months, and 24 months * Research labs at baseline, 6 months,12 months, and 24 months * Age: ≥ 18 years * Female sex assigned at birth * Ability to read and understand English or Spanish for questionnaires * Diagnosis of invasive breast cancer stages I-III * Completed adjuvant treatment for Stage 1-3 breast cancer within 5 years and are disease free. * Women who receive drugs for weight loss - e.g. semaglutide - prior to diagnosis are eligible for this protocol and can continue the drug during the intervention. Exclusion Criteria: * Currently taking metformin or any other oral antidiabetic medications. Weight loss medications are permitted - e.g. semaglutide * Taking tamoxifen or aromatase inhibitor * Contraindication to metformin prevention such as acute hypersensitivity or allergic reaction to metformin * Participants with acute or chronic renal insufficiency (a glomerular filtration rate \[GFR\] \< 60 mL/min/1.73m\^2) or those with acute renal insufficiency of any severity due to hepato-renal syndrome or in the peri-operative liver transplantation period * Bilirubin of \>2.5 mg/dL (normal range 0.1-1.2 mg/dL). * Previously diagnosed type 1 or type 2 diabetes * Patients pregnant or within 1 year of pregnancy and completion of lactation (to be determined at randomization). * Other active malignancy. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures * An employee who is under the direct/indirect supervision of the principal investigator (PI)/a co-investigator/the study manager and/or a direct study team member * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Conditions HER2-positive Early Breast Cancer
Phase PHASE2
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This prospective, response-guided phase II study investigates individualized neoadjuvant treatment strategies for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. After receiving neoadjuvant dual-HER2-targeted therapy with chemotherapy, patients are evaluated for their treatment response. Those achieving an adequate response continue the therapy, whereas patients with a suboptimal response transition to an intensified investigational regimen incorporating novel targeted agents. This adaptive approach aims to optimize pathologic response, minimize unnecessary toxicity, and explore more effective treatment options for individuals with insufficient benefit from conventional neoadjuvant therapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Nab paclitaxel — Nab paclitaxel
  • Drug: Carboplatin — carboplatin
  • Drug: Trastuzumab — trastuzumab
  • Drug: Pertuzumab — pertuzumab
  • Drug: SHR-A1811 — a HER2-targeted antibody-drug conjugate (ADC)
  • Drug: Pyrotinib — Pyrotinib: an oral irreversible pan-HER tyrosine kinase inhibitor (TKI).

Primary Outcomes

  • Total Pathological Complete Response (tpCR) Rate: ypT0/Tis, ypN0 (18 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-12-25
Completion: 2031-01-01
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Contact Information
Study Contact:
Yiding Chen
15868131018
ydchen@zju.edu.cn
Yunxiang Zhou
yxzhou@zju.edu.cn
Yunxiang Zhou
15868131018
yxzhou@zju.edu.cn
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Interventions
  • Drug: Nab paclitaxel — Nab paclitaxel
  • Drug: Carboplatin — carboplatin
  • Drug: Trastuzumab — trastuzumab
  • Drug: Pertuzumab — pertuzumab
  • Drug: SHR-A1811 — a HER2-targeted antibody-drug conjugate (ADC)
Study Locations (1 sites)
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 and ≤75 years. 2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 3. Primary tumor size \>1 cm. 4. Histologically confirmed invasive breast cancer, clinically staged as: * Stage I (T1cN0M0) * Stage II (T1cN1M0, T2N0-1M0 or T3N0M0) * Stage III (T2N2-3M0, T3N1-3M0, or T4N0-3M0) 5. HER2-positive status: IHC 3+ or IHC 2+ with positive ISH. 6. Adequate major organ function: 1. Hematology (no transfusion or hematopoietic growth factors, e.g., G-CSF, within 14 days): * Hemoglobin ≥100 g/L * Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L * Platelet count ≥100 × 10⁹/L 2. Biochemistry: * Total bilirubin ≤1.5 × ULN * ALT and AST ≤1.5 × ULN; ALP ≤2.5 × ULN * BUN and creatinine ≤1.5 × ULN 3. Cardiac function: LVEF ≥55% by echocardiography 7. Women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment and agree to use effective contraception during the study and for 8 weeks after the last dose. 8. Voluntary written informed consent and willingness to comply with study procedures and follow-up. Exclusion Criteria: 1. Prior anti-tumor therapy for breast cancer, including chemotherapy, radiotherapy, targeted therapy, or endocrine therapy. 2. Concurrent administration of any other anti-tumor treatment. 3. Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer. 4. Breast cancer not confirmed histologically. 5. History of other malignancy within the past 5 years, except successfully treated cervical carcinoma in situ. 6. Severe dysfunction of major organs (heart, liver, kidney). 7. Conditions affecting oral drug administration or absorption, e.g., inability to swallow, chronic diarrhea, or intestinal obstruction. 8. Participation in another investigational drug trial within 4 weeks prior to enrollment. 9. Known hypersensitivity to study drug components; history of immunodeficiency (HIV positive, active HCV, active hepatitis B, other congenital/acquired immunodeficiency) or prior organ transplantation. 10. History of clinically significant cardiac disease, including: 1. Arrhythmia requiring medication 2. Myocardial infarction 3. Heart failure 4. Other cardiac conditions deemed unsuitable for study participation by the investigator 11. Pregnant or breastfeeding women, or women of childbearing potential who test positive at baseline or are unwilling to use effective contraception throughout the study. 12. Any condition that, in the investigator's judgment, poses serious risk to patient safety or may interfere with study completion (e.g., uncontrolled severe hypertension, uncontrolled diabetes, active infection). 13. History of neurological or psychiatric disorders (e.g., epilepsy or dementia) or any other condition the investigator considers incompatible with study participation.

IDOV-Immune for Advanced Solid Tumors

NCT06910657
Recruiting
Conditions Colorectal Cancer, Pancreatic Cancer, Me...
Phase PHASE1
Enrollment 78
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer. This study is being conducted at multiple sites in the United States and Australia.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: IDOV-Immune (oncolytic vaccinia virus) — IDOV-Immune is a genetically engineered oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating the immune system. This study investigates IDOV-Immune as a single intravenous infusion in a first-in-human, Phase 1, dose-escalation trial in participants with advanced solid tumors. The dose will escalate based on safety data, with a goal of identifying the recommended Phase 2 dose (RP2D).

Primary Outcomes

  • Incidence of Dose-Limiting Toxicities (DLTs) (From first dose through the end of the DLT evaluation period (28 days))
  • Safety and Tolerability of IDOV-Immune by Dose Level (From first dose through end of treatment (28 days) (and/or safety follow-up period as defined in protocol [90 days]))
  • Determination of the Maximum Tolerated Dose (MTD) (From first dose through completion of dose-escalation cohorts (2 years))
  • Identification of Dose Level(s) for Further Clinical Evaluation (From first dose through completion of dose-escalation and data review (2 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-08-25
Completion: 2027-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 78 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ViroMissile, Inc.
Contact Information
Study Contact:
Clinical Development
858-886-7718
clinicaltrials@viromissile.com
Sara Mitchum
314-273-8602
saram@wustl.edu
Washington University School of Medicine
Investigator
877-632-6789
physicianreferrals@mdanderson.org
MD Anderson Cancer Center
Interventions
  • Biological: IDOV-Immune (oncolytic vaccinia virus) — IDOV-Immune is a genetically engineered oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating the immune system. This study investigates IDOV-Immune as a single intravenous infusion in a first-in-human, Phase 1, dose-escalation trial in participants with advanced solid tumors. The dose will escalate based on safety data, with a goal of identifying the recommended Phase 2 dose (RP2D).
Study Locations (5 sites)
Washington University School of Medicine, St Louis, Missouri 63110 United States
MD Anderson Cancer Center, Houston, Texas 77030 United States
South Texas Accelerated Research Therapeutics, San Antonio, Texas 78229 United States
Westmead Hospital, Westmead, New South Wales 2145 Australia
The Alfred Hospital, Melbourne, Victoria 3004 Australia
Eligibility Criteria
Key Inclusion Criteria: * Age ≥ 18 years. * Histologically or cytologically confirmed advanced solid tumors that have progressed despite standard therapy, or for which no standard therapy exists. * ECOG performance status ≤ 1. * Measurable disease per RECIST v1.1. * Adequate organ and bone marrow function. * At least 28 days since major surgery, prior immunotherapy, or radiotherapy (with exceptions for minor procedures). * Negative pregnancy test for women of childbearing potential. * Agreement to use effective contraception during treatment and for 3 months after. * Ability to provide informed consent and comply with study requirements. Key Exclusion Criteria: * Prior treatment with an oncolytic virus. * Active or recent vaccinia virus infection or smallpox/monkeypox vaccination within 10 years. * Active uncontrolled infection requiring systemic treatment. * History of hepatitis B, hepatitis C, or HIV (unless meeting protocol-specific criteria). * Unresolved ≥ Grade 2 toxicities from prior therapies (except hair loss or stable chronic conditions). * Active or symptomatic autoimmune disease requiring systemic therapy. * Active or untreated CNS metastases (unless stable per protocol). * Significant cardiac disease (e.g., NYHA Class III/IV heart failure). * Interstitial lung disease or prior pneumonitis requiring steroids. * Conditions requiring chronic immunosuppressive therapy. * Severe skin disorders or history of pancreatitis. * Bleeding disorders or history of recent serious thromboembolic events. * Any medical or psychiatric condition that could interfere with study participation.